Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 172)
Posted On: 12/27/2018 5:46:25 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Increases the Performance of Products for Third-Party Partners
- Changing the way cannabinoids and nicotine enter the blood stream
- Enhancing products worldwide, with patents issued and pending in more than 40 countries
- Providing a powerful new delivery method with a cost of less than a penny per serving to implement
Smoking is an efficient way to absorb cannabis and nicotine into the blood stream. However, it is also a health hazard that takes the lives of over six million people each year through smoking-related diseases.
What would it mean for the cannabis, nicotine and other medicinal industries if the dangers of lighting up were eliminated from the equation? What if a more effective way of delivering drugs was developed that reduced quantity and increased effectiveness without the negative side effects? One company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), set out to answer these questions.
Lexaria’s revolutionary technology, DehydraTECH, changed the way that fat soluble, plant-derived molecules (such as cannabinoids and nicotine) enter the body.
The first challenge when creating edibles is taste and smell. Cannabinoids and nicotine can be bitter when taken orally. For this reason, edibles often contain high levels of sugar. DehydraTECH masks the taste and smell, eliminating the need for unhealthy sweeteners while making the product more desirable for the consumer.
Once past the mouth, these molecules do not fully survive the acidic nature of the stomach. Though the ideal location for absorption is in the small intestine, the stomach damages the molecules before they have a chance to arrive. DehydraTECH provides protection during stomach transit and can even bypasses first pass liver metabolism when desired. The truth is that the vast majority of substances orally consumed end up being filtered through the body as waste. With the addition of DehydraTECH, this changes! Bio absorption is increased by five to 10 times.
Four different wholly owned subsidiaries operate under Lexaria. Each is empowered with global exclusive licenses to use and out-license DehydraTECH to third party partners within their respective industries in more than 40 countries where the technology is patented or patent-pending. Partners are offered a competitive edge and protection against inferior methodologies and outdated technology. DehydraTECH is suitable for use in processed foods, beverages, capsules, oral sprays, topical applications and more. Though the company is doing extensive research and evaluating the potential use of its technology for nicotine delivery, it is not partnering with the tobacco industry.
Chemicals or intimidating complex ingredients that require disclosure on food labels are not required additions when using DehydraTECH. Instead the edible tech works with commons GRAS ingredients that can be organic and gluten- and dairy-free. It does all of this while still costing partners less than a penny per serving to implement, making DehydraTECH a win-win for the partner and consumer, who both gain from the improved performance of the enhanced product.
Lexaria believes that one day, using technologies like DehydraTECH, foods and beverages will be able to replace smoking as the most effective delivery mechanism. The work the company is doing with cannabinoids and nicotine is paving a path toward providing a powerful new delivery method of pain relievers, vitamins, supplements and more.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Changing the way cannabinoids and nicotine enter the blood stream
- Enhancing products worldwide, with patents issued and pending in more than 40 countries
- Providing a powerful new delivery method with a cost of less than a penny per serving to implement
Smoking is an efficient way to absorb cannabis and nicotine into the blood stream. However, it is also a health hazard that takes the lives of over six million people each year through smoking-related diseases.
What would it mean for the cannabis, nicotine and other medicinal industries if the dangers of lighting up were eliminated from the equation? What if a more effective way of delivering drugs was developed that reduced quantity and increased effectiveness without the negative side effects? One company, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), set out to answer these questions.
Lexaria’s revolutionary technology, DehydraTECH, changed the way that fat soluble, plant-derived molecules (such as cannabinoids and nicotine) enter the body.
The first challenge when creating edibles is taste and smell. Cannabinoids and nicotine can be bitter when taken orally. For this reason, edibles often contain high levels of sugar. DehydraTECH masks the taste and smell, eliminating the need for unhealthy sweeteners while making the product more desirable for the consumer.
Once past the mouth, these molecules do not fully survive the acidic nature of the stomach. Though the ideal location for absorption is in the small intestine, the stomach damages the molecules before they have a chance to arrive. DehydraTECH provides protection during stomach transit and can even bypasses first pass liver metabolism when desired. The truth is that the vast majority of substances orally consumed end up being filtered through the body as waste. With the addition of DehydraTECH, this changes! Bio absorption is increased by five to 10 times.
Four different wholly owned subsidiaries operate under Lexaria. Each is empowered with global exclusive licenses to use and out-license DehydraTECH to third party partners within their respective industries in more than 40 countries where the technology is patented or patent-pending. Partners are offered a competitive edge and protection against inferior methodologies and outdated technology. DehydraTECH is suitable for use in processed foods, beverages, capsules, oral sprays, topical applications and more. Though the company is doing extensive research and evaluating the potential use of its technology for nicotine delivery, it is not partnering with the tobacco industry.
Chemicals or intimidating complex ingredients that require disclosure on food labels are not required additions when using DehydraTECH. Instead the edible tech works with commons GRAS ingredients that can be organic and gluten- and dairy-free. It does all of this while still costing partners less than a penny per serving to implement, making DehydraTECH a win-win for the partner and consumer, who both gain from the improved performance of the enhanced product.
Lexaria believes that one day, using technologies like DehydraTECH, foods and beverages will be able to replace smoking as the most effective delivery mechanism. The work the company is doing with cannabinoids and nicotine is paving a path toward providing a powerful new delivery method of pain relievers, vitamins, supplements and more.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼